Figure 8
The defective migration of Rnd2 -deficient neurons is restored by co-delivery of Bacurd2:Rnd2. (A,B) The defective migration of Rnd2 shRNA is corrected by co-delivery of Rnd2, Bacurd2:Rnd2 and, to a lesser extent, Bacurd2(3A):Rnd2 (N > 2,000 cells per condition; F 8,39 = 17.36; P < 0.0001; two-way ANOVA by Bonferroni’s post hoc test). (C-E) Cell entry index calculated as the proportion of cells within each subcompartment. Rnd2 shRNA treatment impairs VZ-to-IZ entry, but is corrected by co-delivery of Rnd2, Bacurd2:Rnd2 and Bacurd2(3A):Rnd2 (F 4,13 = 4.210, P = 0.021; one-way ANOVA) (C). Co-delivery of Rnd2 or Bacurd2:Rnd2 restores IZ-to-CP entry of Rnd2 deficient neurons (F 4,13 = 16.31, P < 0.0001; one-way ANOVA) (D), as well as their migration to the upper CP (N > 295 cells per condition; F 4,13 = 18.01, P < 0.0001; one-way ANOVA) (E). Bacurd2(3A):Rnd2 does not significantly improve IZ-to-CP entry (D), nor the intracortical migration of Rnd2-deficient cells (E). (F) The morphology of IZ and CP neurons. (G) Rnd2 shRNA-treated CP neurons show an increase in the proportion of round cells and a concomitant reduction in uni/bipolar shaped cells (N > 250 cells per condition; F 8,57 = 8.64, P < 0.0001; two-way ANOVA followed by Bonferroni’s post hoc test). Co-delivery of Rnd2, Bacurd2:Rnd2 or Bacurd2(3A):Rnd2 restores the morphological profile of Rnd2shRNA-treated neurons within the CP. (H) Rnd2 shRNA-treated IZ neurons show a significant increase in the proportion of multipolar cells and a concomitant reduction in uni/bipolar shaped cells (N > 640 cells per condition; F 8,51 = 3.497, P = 0.0027; two-way ANOVA followed by Bonferroni’s post hoc test). Co-delivery of Rnd2, Bacurd2:Rnd2 and Bacurd2(3A):Rnd2 restored the morphologies of Rnd2 shRNA-treated IZ neurons to control profile. Data was collected from three to four independent brains per condition. Scale bar represents 100 μm (A) and 20 μm (F).